In the latest quarter, 11 analysts provided ratings for Nevro (NYSE:NVRO), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Nevro yesterday announced that the FDA has granted approval for a study evaluating its high-frequency spinal cord stimulation system for the treatment of chronic pain. The device company’s Senza ...

Backed by the likes of Johnson & Johnson and Mayo Clinic, Nevro Corp. has raised $58 million to prepare for a hoped-for U.S. launch of its spinal cord stimulator for chronic pain, according to a ...

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy The published 24-month ...

Nevro is bringing artificial intelligence to its spinal cord stimulation solutions. The Redwood City, CA-based company said it won FDA approval for the HFX iQ with HFX AdaptivAI - a responsive, ...

Spinal Cord Stimulation Coverage Policy to Include 43 Million Additional Covered Lives REDWOOD CITY, Calif., Jan. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* ...

HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...

REDWOOD CITY, Calif., Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...